Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative efficacy and safety of two intranasal triamcinolone acetonide formulations in persistent allergic rhinitis
2005-002742-19Phase 2Terminated
- Sponsor
- Neolab Limited
- Start
- Oct 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of triamcinolone acetonide in persistent allergic rhinitis (PAR) (2 arms), sponsored by Neolab Limited. Primary endpoint: Juniper mini rhinoconjunctivitis quality of life questionnaire (miniRQLQ) score. Started Oct 2005; status: terminated.
02
Drugs
triamcinolone acetonide
03
Conditions
persistent allergic rhinitis (PAR)
Beyond the preview
Go deeper on 2005-002742-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002742-19.